155 related articles for article (PubMed ID: 20225289)
1. Neuroprotective effects of zonisamide target astrocyte.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
[TBL] [Abstract][Full Text] [Related]
2. Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.
Choudhury ME; Moritoyo T; Kubo M; Kyaw WT; Yabe H; Nishikawa N; Nagai M; Matsuda S; Nomoto M
Brain Res; 2011 Apr; 1384():170-8. PubMed ID: 21320474
[TBL] [Abstract][Full Text] [Related]
3. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
[TBL] [Abstract][Full Text] [Related]
5. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
6. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
7. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Kato H; Kurosaki R; Oki C; Araki T
Brain Res; 2004 Dec; 1030(1):66-73. PubMed ID: 15567338
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
9. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
10. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
[TBL] [Abstract][Full Text] [Related]
11. Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
Miyazaki I; Asanuma M; Murakami S; Takeshima M; Torigoe N; Kitamura Y; Miyoshi K
Neurobiol Dis; 2013 Nov; 59():244-56. PubMed ID: 23959140
[TBL] [Abstract][Full Text] [Related]
12. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
13. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
Yasuhara T; Shingo T; Muraoka K; wen Ji Y; Kameda M; Takeuchi A; Yano A; Nishio S; Matsui T; Miyoshi Y; Hamada H; Date I
Brain Res; 2005 Mar; 1038(1):1-10. PubMed ID: 15748867
[TBL] [Abstract][Full Text] [Related]
14. Zonisamide: a new drug for Parkinson's disease.
Murata M
Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
16. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors.
Choudhury ME; Sugimoto K; Kubo M; Iwaki H; Tsujii T; Kyaw WT; Nishikawa N; Nagai M; Tanaka J; Nomoto M
Eur J Pharmacol; 2012 Aug; 689(1-3):72-80. PubMed ID: 22659113
[TBL] [Abstract][Full Text] [Related]
17. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
Murata M
Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
[TBL] [Abstract][Full Text] [Related]
19. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
